86647
document
Synthetic serum substitute ( SSS ) : a globulin-enriched protein supplement for human embryo culture . OBJECTIVE The purpose of the present study was to evaluate whether an IVF protein supplement prepared from human serum albumin ( HSA ) and human globulins would retain performance characteristics equivalent to those reported for the commercial plasma expanders , Plasmatein ( Alpha Therapeutics , Los Angeles , California ) and Plasmanate ( Cutter Biological , Miles Inc. , Elkhart , Indiana ) . METHODS Pronuclear-stage human embryos were randomly divided and cultured in human tubal fluid medium ( HTF ) supplemented with either HSA ( 5 mg/mL ) or Plasmatein ( 10 % , v/v ; 5 mg/ml ) as a means of indirectly assessing the effect alpha- and beta-globulins have on embryonic development . Those results coupled with the known composition characteristics of Plasmatein were used as the starting basis to formulate test lots of synthetic serum substitute ( SSS ) . RESULTS Significantly ( P < 0.05 ) more of the human embryos cultured in Plasmatein supplemented medium reached the four-cell or greater stage by 40 hr postinsemination than a comparable group cultured in HSA alone . Lot 1 of SSS , formulated with HSA ( 84 % of total protein ) and human globulins ( 16 % of total protein ) and an aqueous lipoprotein fraction derived from human plasma ( Excyte IV ; Miles Diagnostics , Kankakee , Illinois ) , produced accelerated early embryonic growth relative to control murine embryos grown in the presence of Plasmatein , however , the percentage of the embryos reaching the hatched blastocyst stage was decreased ( 45 vs 100 % ) . Human embryos from seven patients , randomized to HTF medium supplemented with Plasmatein or lot 1 of SSS , showed equivalent growth at 36-40 hr postinsemination . A microprecipitate developed in media supplemented with lot 1 after several days of culture . The Excyte IV concentration was reduced and , ultimately , eliminated from the subsequent and final prototype lots of SSS . Murine embryos grown in the presence of lipoprotein free SSS showed significantly accelerated ( P < 0.01 ) growth at 17 hr postthaw compared to Plasmatein and all embryos progressed to hatching by 41 hr . Human embryos , randomized to either Plasmatein or lot 3 of SSS , showed significantly accelerated growth ( P < 0.01 ) when scored at 38 hr following insemination . CONCLUSION Synthetic serum substitute provides a convient , standardized means of adding protein to media used in assisted reproductive technology ( ART ) procedures .
86648
Intervention_Pharmacological
Synthetic serum substitute ( SSS )
86649
Intervention_Pharmacological
Plasmatein
86650
Intervention_Pharmacological
Plasmanate
86651
Intervention_Pharmacological
human tubal fluid medium ( HTF )
86652
Intervention_Pharmacological
HSA ( 5 mg/mL )
86653
Intervention_Pharmacological
( 10 % , v/v ; 5 mg/ml )
86654
Intervention_Pharmacological
Plasmatein
86655
Intervention_Pharmacological
Plasmatein
86656
Intervention_Pharmacological
HSA
86657
Intervention_Pharmacological
Plasmatein
86658
Intervention_Pharmacological
SSS
86659
Intervention_Pharmacological
SSS
86660
Intervention_Pharmacological
Plasmatein
86661
Intervention_Pharmacological
Plasmatein
86662
Intervention_Pharmacological
SSS
86663
Intervention_Pharmacological
Synthetic serum substitute
86664
Outcome_Mental
performance characteristics
86665
Outcome_Physical
four-cell or greater stage
86666
Outcome_Physical
early embryonic growth
86667
Outcome_Physical
growth
86668
Outcome_Physical
Excyte IV concentration
86669
Outcome_Physical
accelerated ( P < 0.01 ) growth
86670
Outcome_Physical
hatching
86671
Outcome_Physical
accelerated growth
86672
Participant_Sample-size
seven